Natriuretic Peptides and Metabolic Risk in Obesity

• Status: Withdrawn
• Trial end date: 2017-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators are examining:

1. the relationships of insulin levels and natriuretic peptide hormone levels, and

2. the effects of administering an infusion of natriuretic peptide hormone on the breakdown of fat

in healthy lean and otherwise healthy obese individuals.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Vanderbilt University; Vanderbilt University Medical Center
• Treatments: Insulin; Insulin, Globin Zinc; Natriuretic Peptide, Brain

Criteria

Inclusion Criteria:

• Men and women ages 18-50 years

• BMI 18 to <25 kg/m2 (lean group, N=20) or BMI 30 to <40 kg/m2 (obese group, N=20)

Exclusion Criteria:

• Current use of antihypertensive medications

• Current use of glucocorticoids, metformin, or any antidiabetes medications

• Prior or current cardiovascular disease, renal disease, or liver disease

• Diabetes mellitus (taking insulin, other anti-diabetic agents, or diet-controlled)

• Atrial fibrillation

• Bleeding disorder or anemia

• Elevated LFTs

• estimuated GFR < 60 ml/min

• Abnormal sodium or potassium level

• Positive pregnancy test, women of child-bearing age not practicing birth control, women who are breastfeeding